User login
Key clinical point: Apatinib plus programmed cell death protein 1 (PD-1) inhibitors show promising response and acceptable tolerance in previously treated real-world patients with advanced gastric cancer.
Major finding: The median follow-up duration was 7.3 months. The objective response rate was 20.5% and disease control rate was 69.2%. The median progression-free survival (PFS) was 3.9 months (95% CI 2.74-5.06), and the median overall survival (OS) was 7.8 (95% CI 4.82-10.78) months. The most common adverse events were fatigue (61.5%), nausea and vomiting (56.4%), diarrhea (48.7%), hypertension (46.2%), hand-foot syndrome (38.5%), and rash (28.2%).
Study details: This was a real-world study of 39 previously treated patients with advanced gastric cancer who received apatinib plus PD-1 blockade treatment between August 2018 and October 2021.
Disclosures: This study was supported by the Natural Science Foundation of Henan Province, China. The authors declared no conflicts of interest.
Source: Li LH et al. Feasibility and tolerance of apatinib plus PD-1 Inhibitors for previously treated;advanced gastric cancer: A real-world exploratory study. Dis Markers. 2022; 4322404 (Apr 29). Doi: 10.1155/2022/4322404
Key clinical point: Apatinib plus programmed cell death protein 1 (PD-1) inhibitors show promising response and acceptable tolerance in previously treated real-world patients with advanced gastric cancer.
Major finding: The median follow-up duration was 7.3 months. The objective response rate was 20.5% and disease control rate was 69.2%. The median progression-free survival (PFS) was 3.9 months (95% CI 2.74-5.06), and the median overall survival (OS) was 7.8 (95% CI 4.82-10.78) months. The most common adverse events were fatigue (61.5%), nausea and vomiting (56.4%), diarrhea (48.7%), hypertension (46.2%), hand-foot syndrome (38.5%), and rash (28.2%).
Study details: This was a real-world study of 39 previously treated patients with advanced gastric cancer who received apatinib plus PD-1 blockade treatment between August 2018 and October 2021.
Disclosures: This study was supported by the Natural Science Foundation of Henan Province, China. The authors declared no conflicts of interest.
Source: Li LH et al. Feasibility and tolerance of apatinib plus PD-1 Inhibitors for previously treated;advanced gastric cancer: A real-world exploratory study. Dis Markers. 2022; 4322404 (Apr 29). Doi: 10.1155/2022/4322404
Key clinical point: Apatinib plus programmed cell death protein 1 (PD-1) inhibitors show promising response and acceptable tolerance in previously treated real-world patients with advanced gastric cancer.
Major finding: The median follow-up duration was 7.3 months. The objective response rate was 20.5% and disease control rate was 69.2%. The median progression-free survival (PFS) was 3.9 months (95% CI 2.74-5.06), and the median overall survival (OS) was 7.8 (95% CI 4.82-10.78) months. The most common adverse events were fatigue (61.5%), nausea and vomiting (56.4%), diarrhea (48.7%), hypertension (46.2%), hand-foot syndrome (38.5%), and rash (28.2%).
Study details: This was a real-world study of 39 previously treated patients with advanced gastric cancer who received apatinib plus PD-1 blockade treatment between August 2018 and October 2021.
Disclosures: This study was supported by the Natural Science Foundation of Henan Province, China. The authors declared no conflicts of interest.
Source: Li LH et al. Feasibility and tolerance of apatinib plus PD-1 Inhibitors for previously treated;advanced gastric cancer: A real-world exploratory study. Dis Markers. 2022; 4322404 (Apr 29). Doi: 10.1155/2022/4322404